Your browser doesn't support javascript.
Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2.
Xu, Kun; Gao, Ping; Liu, Sheng; Lu, Shuaiyao; Lei, Wenwen; Zheng, Tianyi; Liu, Xueyuan; Xie, Yufeng; Zhao, Zhennan; Guo, Shuxin; Tang, Cong; Yang, Yun; Yu, Wenhai; Wang, Junbin; Zhou, Yanan; Huang, Qing; Liu, Chuanyu; An, Yaling; Zhang, Rong; Han, Yuxuan; Duan, Minrun; Wang, Shaofeng; Yang, Chenxi; Wu, Changwei; Liu, Xiaoya; She, Guangbiao; Liu, Yan; Zhao, Xin; Xu, Ke; Qi, Jianxun; Wu, Guizhen; Peng, Xiaozhong; Dai, Lianpan; Wang, Peiyi; Gao, George F.
  • Xu K; Research Network of Immunity and Health (RNIH), Beijing Institutes of Life Science, Chinese Academy of Sciences, Beijing 100101, China.
  • Gao P; CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China; University of Chinese Academy of Sciences, Beijing 100049, China.
  • Liu S; Cryo-EM Center, Southern University of Science and Technology, Shenzhen 518055, China.
  • Lu S; National Kunming High-level Biosafety Primate Research Center, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming 650031, China.
  • Lei W; NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.
  • Zheng T; Zhejiang University School of Medicine, Hangzhou 310058, China.
  • Liu X; School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan 250012, China.
  • Xie Y; Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing 100084, China.
  • Zhao Z; CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China; University of Chinese Academy of Sciences, Beijing 100049, China.
  • Guo S; Faculty of Health Sciences, University of Macau, Macau, SAR 999078, China.
  • Tang C; National Kunming High-level Biosafety Primate Research Center, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming 650031, China.
  • Yang Y; National Kunming High-level Biosafety Primate Research Center, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming 650031, China.
  • Yu W; National Kunming High-level Biosafety Primate Research Center, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming 650031, China.
  • Wang J; National Kunming High-level Biosafety Primate Research Center, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming 650031, China.
  • Zhou Y; National Kunming High-level Biosafety Primate Research Center, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming 650031, China.
  • Huang Q; National Kunming High-level Biosafety Primate Research Center, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming 650031, China.
  • Liu C; State Key Laboratory for Conservation and Utilization of Subtropical Agro-Bioresources, Guangxi University, Nanning 530004, China.
  • An Y; Savaid Medical School, University of Chinese Academy of Sciences, Beijing 101408, China.
  • Zhang R; State Key Laboratory for Conservation and Utilization of Subtropical Agro-Bioresources, Guangxi University, Nanning 530004, China.
  • Han Y; Savaid Medical School, University of Chinese Academy of Sciences, Beijing 101408, China.
  • Duan M; School of Life Sciences, Yunnan University, Kunming 650091, China.
  • Wang S; CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China; University of Chinese Academy of Sciences, Beijing 100049, China.
  • Yang C; CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China; University of Chinese Academy of Sciences, Beijing 100049, China.
  • Wu C; Anhui Zhifei Longcom Biopharmaceutical Co. Ltd, Hefei 230088, China.
  • Liu X; Anhui Zhifei Longcom Biopharmaceutical Co. Ltd, Hefei 230088, China.
  • She G; Anhui Zhifei Longcom Biopharmaceutical Co. Ltd, Hefei 230088, China.
  • Liu Y; Chongqing Medleader Bio-Pharm, Chongqing 401338, China.
  • Zhao X; CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China.
  • Xu K; NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.
  • Qi J; CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China.
  • Wu G; NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China. Electronic address: wugz@ivdc.chinacdc.cn.
  • Peng X; National Kunming High-level Biosafety Primate Research Center, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming 650031, China; State Key Laboratory of Medical Molecular Biology, Department of Molecular Biology and Biochemistry, Institute of
  • Dai L; CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China; University of Chinese Academy of Sciences, Beijing 100049, China. Electronic address: dailp@im.ac.cn.
  • Wang P; Cryo-EM Center, Southern University of Science and Technology, Shenzhen 518055, China. Electronic address: wangpy@sustech.edu.cn.
  • Gao GF; Research Network of Immunity and Health (RNIH), Beijing Institutes of Life Science, Chinese Academy of Sciences, Beijing 100101, China; CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China; University of Chinese Aca
Cell ; 185(13): 2265-2278.e14, 2022 06 23.
Article in English | MEDLINE | ID: covidwho-1803705
ABSTRACT
Breakthrough infections by SARS-CoV-2 variants become the global challenge for pandemic control. Previously, we developed the protein subunit vaccine ZF2001 based on the dimeric receptor-binding domain (RBD) of prototype SARS-CoV-2. Here, we developed a chimeric RBD-dimer vaccine approach to adapt SARS-CoV-2 variants. A prototype-Beta chimeric RBD-dimer was first designed to adapt the resistant Beta variant. Compared with its homotypic forms, the chimeric vaccine elicited broader sera neutralization of variants and conferred better protection in mice. The protection of the chimeric vaccine was further verified in macaques. This approach was generalized to develop Delta-Omicron chimeric RBD-dimer to adapt the currently prevalent variants. Again, the chimeric vaccine elicited broader sera neutralization of SARS-CoV-2 variants and conferred better protection against challenge by either Delta or Omicron SARS-CoV-2 in mice. The chimeric approach is applicable for rapid updating of immunogens, and our data supported the use of variant-adapted multivalent vaccine against circulating and emerging variants.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines / COVID-19 Topics: Vaccines / Variants Limits: Animals / Humans Language: English Journal: Cell Year: 2022 Document Type: Article Affiliation country: J.cell.2022.04.029

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines / COVID-19 Topics: Vaccines / Variants Limits: Animals / Humans Language: English Journal: Cell Year: 2022 Document Type: Article Affiliation country: J.cell.2022.04.029